When Okamoto and his associates began their systematic search in 1947 for a synthetic inhibitor of fibrinolysis they aimed to find a substance of value in clinical conditions in which hyperplasminaemia was significant-conditions such as excessive bleeding associated with prostatic and thoracic surgery and with abruptio placentae. They discovered two potent inhibitors of fibrinolysis, epsilon-aminocaproic acid (EACA)l and tranexamic acid (aminomethyl-cyclohexane carboxylic acid) (AMCA).2 Both drugs have been used with mixed success in a variety of clinical conditions during the past 20 years. I shall confine myself to their use in treating haemophilia (factor VIII deficiency) or Christmas disease (factor IX deficiency). A third inhibitor of fibrinolysis, aprotinin (Trasylol), prepared from bovine lung is also commercially available. In addition to acting as an inhibitor of plasmin and plasminogen activator it has a weak anticoagulant action. It has been very little used in haemophilia except as an instillation into joints during some forms of joint surgery and will not be discussed.
Epsilon-aminocaproic acid (EACA)
Okamoto and his associates thought that EACA acted by inhibiting plasmin, but Alkjaersig et al. 3 showed that it was principally a competitive inhibitor of plasminogen activator and acted in this respect in vivo at a concentration of 0-1 mmol/l. Higher concentrations of the order of 50 mmol/l were required to inhibit plasmin. There followed several reports of the use of peanuts or various extracts of peanuts in the management of haemophilia, mostly in uncontrolled studies. In 1967 .Verstraete and Ruys16 reported a controlled trial in which they found no benefit from the ingestion of peanuts or extracts of peanuts. Despite this, the idea that increased fibrinolysis might be important in haemophilia persisted, and numerous investigations have been made of the effect of epsilon-aminocaproic acid or tranexamic acid in bleeding in haemophilia.
Antifibrinolytic drugs have been used in haemophilia mainly in three ways: (1) for treating haematuria, (2) EACA has been used since 1964 for the management of haemophiliacs undergoing dental extraction. The rationale of its use is to inhibit the local fibrinolytic activity in the tissues and saliva which contributes to lysis of clots in the tooth sockets 2-3 days after operation. EACA was given before and after extraction in 11 haemophiliacs for the removal of a total of 31 teeth.32 Apart from careful packing of the sockets and protecting the gums no other treatment was given. No tranfusions were given at the time of operation and none was required afterwards. Similar results were reported by Cooksey, Perry, and Raper33 who found that EACA therapy along with suturing the sockets produced more adequate haemostasis than the conventional transfusion combined with local measures. Tavennerm used EACA in 61 dental extractions and found that, compared with the period before 1964 when he did not use EACA, the average time in hospital and the amount of transfusion required was reduced.
Although it was difficult to make an accurate assessment, EACA seemed to him to be of undoubted value.
In a double-blind study35 31 patients having dental extractions were given enough factor VIII or IX immediately before surgery to raise their factor concentration to 50 % of normal. At the same -time they also received EACA 6 g or placebo intravenously followed by EACA 6 g or placebo 6-hourly for 7-10 days. All patients also received penicillin or erythromycin to control oral infection. Bleeding from tooth sockets occurred in all except one of the 12 control patients on 46 out of a possible 132 days. In the EACA treatment group three out of 11 patients bled. Seven of the 12 control patients required postoperative treatment whereas only one of the 11 patients in the EACA group bled enough to need attention. This study showed conclusively that EACA is a useful adjunct to transfusion therapy and saves factor VIII or factor IX. Similar results were obtained by Forbes and his associates36 with AMCA in haemophiliacs undergoing dental extraction. In a double-blind study 28 patients received a transfusion of factor VIII or IX equivalent to 1000 ml plasma and 1 g AMCA or placebo three times a day for five days. Blood loss was measured by 51Cr-labelled red cells. It was significantly reduced in patients receiving AMCA compared with the placebo group. There seems little doubt now that both EACA and AMCA have a part to play in dental extractions in haemophiliacs, but because of its lack of side effects AMCA has largely superseded EACA and is probably the drug of choice.
Oral bleeding apart from that from dental extraction is common in younghaemophiliacs, usually from injury to the tongue or fraenulum. Because the bleeding is often insignificant and because of the distress often caused by venepuncture and transfusion many doctors give inhibitors of fibrinolysis either alone or with a single dose of factor VIII or IX in these cases. Corrigan37 successfully used combined EACA and factor replacement therapy in 10 haemophilic children with bleeding from the mouth not associated with dental extraction. His regimen was a single dose of cryoprecipitate (2 bags/ 10 kg body weight) followed by 41 Nevertheless, by their very nature those concentrates are potentially thrombogenic, and this must be taken into account when planning combined therapy with factor IX concentrates and inhibitors of fibrinolysis.
Having said that, I must add that our practice is to use EACA or AMCA in factor IX-deficient patients in the same way as we do in those deficient in factor VIII. So far we have not seen any thromboembolic complications with combined factor IX and antifibrinolytic therapy even in patients undergoing total hip replacement and requiring factor IX replacement for 2-3 weeks.
Conclusion
Epsilon-aminocaproic acid and tranexamic acid are both of value in haemophiliacs undergoing dental surgery, and their use has resulted in a considerable saving of coagulation factor concentrates at the time of operation. Three out of four controlled trials of their use in the prophylactic treatment of spontaneous bleeding in haemophilia have failed to show that they significantly reduce the number or severity of bleeds. Nevertheless, one of the trials did show some reduction in the incidence of bleeding, and further studies would be justified. EACA and AMCA both seem to be effective in the control of haematuria in haemophilia either when given alone or with conventional coagulation factor therapy. But the risk of renal tract obstruction is so high that it is probably wiser to treat the haematuria by other means.
